Allogeneic Treg-derived artificial vesicles: A promising therapeutic modality for multiple sclerosis
Developing effective MS therapies remains challenging. While cellular therapies face limitations like Treg dysfunction and CNS delivery issues, allogeneic EVs offer a promising alternative due to their scalability, low immunogenicity, and blood-brain barrier penetration. We developed Treg-derived artificial vesicles (TrAVs) that maintain immunosuppressive properties and modulate PBMC responses, suggesting therapeutic potential for MS. Further research is needed to optimize production and validate efficacy in disease models.
Authors
- A.M. Rogov (ORCID: https://orcid.org/0000-0002-7086-4280)
- Irina Ganeeva (ORCID: https://orcid.org/0000-0003-4041-5000)
- Artur Khannanov (ORCID: https://orcid.org/0000-0001-5119-8449)
- Ekaterina Zmievskaya (ORCID: https://orcid.org/0000-0003-1337-4370)
- Emil Bulatov (ORCID: https://orcid.org/0000-0003-2961-0032)
- Elvina Gilyazova
- Т И Хайбуллин (ORCID: https://orcid.org/0000-0002-5009-6683)
- Mariia Eugenievna Nektorova
Institutions
- Kazan Federal University (RU)
- Institute of Bioorganic Chemistry (RU)
- Kazan State Medical Academy (RU)
Publication Details
- Journal
- Bioimpacts
- Published
- 2025-08-20
- DOI
- https://doi.org/10.34172/bi.30880
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Russian Science Foundation
- Kazan Federal University